Clinical trial NCT05339087: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Official title: Efficacy and Safety of Riociguat (MK-4836) in Incipient Pulmonary Vascular Disease as an Indicator for Early Pulmonary Arterial Hypertension Double-blind, Randomized, Multicenter, Multinational, Placebo-controlled Phase IIa Study (ESRA)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Pulmonary Vascular Disorder
Primary Pulmonary Hypertension
Systemic Sclerosis
Other Systemic Involvement of Connective Tissue
Keywords: early pulmonary vascular disease
riociguat
pulmonary hypertension
Lead sponsor: Heidelberg University
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2022-04-21
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized controlled trial
Primary purpose: TREATMENT

Brief summary: This is a randomized, double-blind, placebo-controlled, multicenter, multinational study investigating the effect of riociguat (MK-4836) in patients with early pulmonary vascular disease.

Detailed description: Chronic pulmonary arterial hypertension (PAH) is associated with impaired exercise capacity, quality of life and right ventricular function characterized by an increase of pulmonary vascular resistance (PVR) and pulmonary arterial pressure, leading to right heart insufficiency.

Riociguat tratment is approved for both PAH and chronic thromboembolic pulmonary hypertension (CTEPH).

Data on early treatment of patients with mildly elevated pulmonary arterial pressures is still scarce but there is evindence that such patients may benefit from early targeted therapy.

For instance, in a trial on systemic sclerosis (SSc)-patients with mildly elevated mean pulmonary artery pressure (mPAP) and/or exercise pulmonary hypertension, without significant left heart or lung disease, ambrisentan, an endothelin receptor antagonist resulted in an improvement of PVR as secondary endpoint, which may be of prognostic relevance in this patient cohort and requires further research.

Besides its prognostic significance among patients with SSc-APAH, PVR may be an indicator of early pulmonary vascular disease and previous studies proved the positive effects of riociguat on right heart size and PVR (secondary endpoint in phase III studies). Thus, PVR was chosen as primary endpoint of this study aiming to investigate the effect of riociguat (MK-4836) on PVR, clinical parameters, safety and tolerability in patients with early pulmonary vascular disease.

Eligible subjects will be randomized in a 1:1 ratio to receive either riociguat or placebo.

Medical examinations include medical history, physical examination, electrocardiogram, blood gas analyses, lung function tests, laboratory testing (including NT-proBNP), echocardiography at rest, and right heart catheterization.

The prospective period of data collection comprises a 24-week treatment phase diveded into an 8-week titration phase followed by a 16-week main study phase as well as a safety follow-up of 30±14 days.

Eligibility criteria: Inclusion Criteria:

1. ≥18 years of age at time of inclusion.
2. Male and female patients with early pulmonary vascular disease, defined as either a) mean pulmonary arterial pressure (mPAP) ≥25 mmHg with pulmonary vascular resistance (PVR) ≥2 to \<3 WU and pulmonary arterial wedge pressure (PAWP) ≤15 mmHg or b) mPAP 21-\<25 mmHg with PVR ≥2 WU, and PAWP ≤15 mmHg associated with connective tissue disease (CTD) or as idiopathic/heritable form (see Group I / Nice Clinical Classification of Pulmonary Hypertension) (acc. to Simonneau et al. 2019). Patients with rheumatoid arthritis or connective tissue disease of any kind, except systemic lupus erythematosus, may also be included. Patients in group b will be mainly enrolled as long as patients in group a are not defined as having pulmonary arterial hypertension according to European pulmonary hypertension guidelines.
3. Treatment naïve patients (with respect to PAH specific medication)
4. Unspecific treatments which may also be used for the treatment of pulmonary hypertension such as oral anticoagulants, diuretics, digitalis, calcium channel blockers or oxygen supplementation are permitted. Permitted are also treatments of the rheumatologic disease. However, these drugs must have been started at least 1 month before right heart catheterization.
5. Right-heart catheterization results must not be older than 1 month at Visit 1 (will be considered as baseline values, the time frame can be prolonged up to 6 months, if the patient has had no signs of clinical changes defined as \>10% change of 6MWD, WHO FC, \> 30% change in NT-proBNP) and must have been measured in the participating center under standardized conditions (refer to the study specific Swan Ganz catheterization manual). If the respective measurements have not been performed in context with the patient's regular diagnostic work up, they have to be performed as a part of the study during the pre-study phase (after the patient signed the informed consent).
6. Women without childbearing potential defined as postmenopausal women aged 55 years or older, women with bilateral tubal ligation, women with bilateral ovariectomy, and women with hysterectomy can be included in the study.
7. Women of childbearing potential can only be included in the study if all of the following applies (listed below):

   1. Negative serum pregnancy test at screening and at study start (visit 1).
   2. Agreement to undertake monthly urine pregnancy tests during the study and up to at least 30 days after study treatment discontinuation. These tests should be performed by the patient at home.
   3. Agreement to use a highly effective contraception method as specified from screening until at least 30 days after last dose of study medication.
8. Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period.
9. Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures.

Exclusion Criteria:

1. Patients with systemic lupus erythematosus.
2. Concomitant PAH-targeted treatment is not allowed during the study.
3. Concomitant treatment with phosphodiesterase 5 inhibitors, endothelin receptor antagonists and prostacyclin analogues due to digital ulcers is contraindicated and must not be taken during the study period. Such drugs must have a washout-phase of 3 days at the time of right heart catheterization at screening. Intravenous treatment with prostacyclin analogues should not be performed within 1 week of right heart catheterization. Any decision to discontinue above-mentioned drugs will be made by the clinicians and the patient at screening, which takes part during the patients' regular routine visit. The discontinuation of above-mentioned drugs will be evaluated by considering the presence or absence of digital ulcers and their frequency of appearance in the patient's medical history.
4. Pulmonary hypertension explained by other cause including group 2, 3, 4 and 5 PH according to the current guidelines.
5. Cardiac comorbidity, defined with three or more of the following conditions: uncontrolled arterial hypertension, diabetes mellitus, body mass index \>35, left atrial enlargement \>20 cm², atrial fibrillation, left ventricular ejection fraction \<50%.
6. Pulmonary comorbidity, defined as forced vital capacity (FVC) ≤70; forced expiratory volume in 1 second (FEV1) ≤50%; diffusion capacity of the lung (DLCO) ≤40%. FVC may be \<70/ if high resolution computed tomography shows \<20% lung fibrosis.
7. Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator.
8. Patients with underlying medical disorders with an anticipated life expectancy below 2 years (e.g. active cancer disease with localized and/or metastasized tumor mass).
9. Patients with a history of severe or multiple drug allergies (defined as allergic reactions to three or more structurally unrelated drugs).
10. Patients with hypersensitivity to the investigational drug or any of the excipients.
11. Contraindications according to summary of product characteristics of riociguat (e.g. arterial hypotension with systolic blood pressure \<95 mmHg; nitrates)
12. Participation in any clinical drug trial within 4 weeks prior to screening of this study and/or patient, who is scheduled to receive an investigational medicinal product (IMP) during the course of this study
13. Background therapy with highly anti-fibrotic drugs (pirfenidone) or nintedanib, prednisolone \>10 mg/day

Primary outcomes:
measure: change of PVR
timeFrame: baseline to 24 weeks
Secondary outcomes:
measure: change of cardiac index at rest
timeFrame: baseline to 24 weeks
measure: change of total pulmonary resistance
timeFrame: baseline to 24 weeks
measure: change of diffusion capacity of the lung
timeFrame: baseline to 24 weeks
measure: change of 6-minute walking distance
timeFrame: baseline to 24 weeks
measure: change of WHO functional class
timeFrame: baseline to 24 weeks
measure: change in quality of life
timeFrame: baseline to 24 weeks
Other outcomes:
measure: change in WHO functional class
timeFrame: baseline to 12 weeks
measure: change in quality of life
timeFrame: baseline to 12 weeks
measure: FEV1 (forced expiratory volume in 1 second)
timeFrame: baseline to 24 weeks
measure: TLC (total lung capacity)
timeFrame: baseline to 24 weeks
measure: DLCO (diffusing capacity of the lung)
timeFrame: baseline to 24 weeks
measure: sPAP (systolic pulmonary arterial pressure)
timeFrame: baseline to 24 weeks
measure: RV-area (right ventricular area)
timeFrame: baseline to 24 weeks
measure: RA-area (right atrial area)
timeFrame: baseline to 24 weeks
measure: TAPSE (tricuspid annular plane systolic excursion)
timeFrame: baseline to 24 weeks
measure: LV-EI (left ventricular eccentricity index)
timeFrame: baseline to 24 weeks
measure: NT-pro BNP
timeFrame: baseline to 12 weeks
measure: NT-pro BNP
timeFrame: baseline to 24 weeks
measure: oxygen partial pressure
timeFrame: baseline to 24 weeks
measure: carbon dioxide partial pressure
timeFrame: baseline to 24 weeks
measure: oxygen saturation of the blood (SpO2)
timeFrame: baseline to 24 weeks
measure: pH
timeFrame: baseline to 24 weeks
measure: bicarbonates
timeFrame: baseline to 24 weeks
measure: base excess
timeFrame: baseline to 24 weeks
measure: sPAP
timeFrame: baseline to 24 weeks
measure: mPAP
timeFrame: baseline to 24 weeks
measure: dPAP (diastolic pulmonary artery pressure)
timeFrame: baseline to 24 weeks
measure: PAWP (pulmonary artery wedge pressure)
timeFrame: baseline to 24 weeks
measure: RAP (right atrial pressure)
timeFrame: baseline to 24 weeks
measure: cardiac output and ejection fraction (CO)
timeFrame: baseline to 24 weeks
measure: central venous saturation (SvO2)
timeFrame: baseline to 24 weeks
Locations:
city: Graz
country: Austria
facility: LKH-Univ. Klinikum Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Pulmonologie
city: Linz
country: Austria
facility: Ordensklinikum Linz GmbH Elisabethinen
city: Lille
country: France
facility: Centre de référence des Maladies Auto-Immunes Systémiques rares du Nord et Nord-Ouest (CeRAINO) Service de Médecine Interne et Immunologie Clinique Hôpital Claude Huriez, CHU
city: Dresden
country: Germany
facility: Carl Gustav Carus University Hospital at the TU Dresden, Medical Department I, Center for PH
city: Heidelberg
country: Germany
facility: Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital Heidelberg
city: Napoli
country: Italy
facility: Università Degli Studi Di Napoli Federico II Scuola Di Medicina E Chirurgia
city: Zürich
country: Switzerland
facility: Universitätsspital Zürich Pulmonale Hypertonie, Klinik für Pneumologie
city: London
country: United Kingdom
facility: Royal Free London NHS Foundation Trust
Study officials:
affiliation: Thoraxklinik at the University of Heidelberg
name: Ekkehard Grünig, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016 Feb;69(2):177. doi: 10.1016/j.rec.2016.01.002. No abstract available.
citation: Grunig E, Barner A, Bell M, Claussen M, Dandel M, Dumitrescu D, Gorenflo M, Holt S, Kovacs G, Ley S, Meyer JF, Pabst S, Riemekasten G, Saur J, Schwaiblmair M, Seck C, Sinn L, Sorichter S, Winkler J, Leuchte HH. [Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with commentary of the Cologne Consensus Conference 2010]. Dtsch Med Wochenschr. 2010 Oct;135 Suppl 3:S67-77. doi: 10.1055/s-0030-1263314. Epub 2010 Sep 22. German.
citation: Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013 Jul 25;369(4):319-29. doi: 10.1056/NEJMoa1209657.
citation: Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, Cittadini A, Coghlan G, Denton CP, Distler O, Egenlauf B, Fischer C, Harutyunova S, Xanthouli P, Lorenz HM, Grunig E. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Res Ther. 2019 Oct 26;21(1):217. doi: 10.1186/s13075-019-1981-0.
citation: Rubin LJ, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani HA. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015 May;45(5):1303-13. doi: 10.1183/09031936.00090614. Epub 2015 Jan 22.